Download PDF

1. Company Snapshot

1.a. Company Description

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally.The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.It also provides analgesics; sore throat medications; and hair removal products under the Nurofen, Strepsils, and Veet brands.


In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; fabric washing; and other hygiene products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as analgesics, adult nutrition products, iron-fortified hypoallergenic baby formula, products for joint issues, and infant and toddler nutrition products, as well as vitamins, minerals, and supplements under the Biofreeze, Airborne, Mead Johnson, Move Free, Enfamil, and Nutramigen brands.Further, it provides probiotics, sore throat pain relief products, Omega products, brain health support products, cleaning and carpet cleaning products, septic tank system treatment products, cough syrups, plant-based laundry products, probiotics, and lubricants under the Digestive Advantage, Cepacol, MegaRed, Neuriva, Easy-Off, RID-X, Delsym, Botanical Origin, Bodi-Ome, and K-Y brands.The company was founded in 1819 and is headquartered in Slough, the United Kingdom.

Show Full description

1.b. Last Insights on RKT

Reckitt Benckiser's recent earnings may be undermined by weak foundations, with analysts adjusting the fair value estimate downward to £64.42. The company's growth prospects are uncertain, with mixed signals from analysts and a trimmed fair value estimate. According to Zacks, Reckitt Benckiser has been added to the Strong Sell list, citing concerns about the company's ability to balance growth, portfolio changes, and returns to shareholders.

1.c. Company Highlights

2. Reckitt's FY2025 Results: Strong Performance in Emerging Markets

Reckitt delivered a robust financial performance in FY2025, with core net revenue growing 5.2%, ahead of the improved guidance of above 4%. The group's net revenue increased 5%, driven by Emerging Markets, where China and India grew double-digits in Q4. Adjusted operating profit rose 5.3%, with Core Reckitt margins expanding 90 basis points to 26.7%. EPS grew 1.1% to 352.8p, supported by the ongoing share buyback program. The actual EPS came in at 1.86, slightly below estimates of 1.9.

Publication Date: Mar -06

📋 Highlights
  • Emerging Markets Growth:: Core Reckitt sales in Emerging Markets surged 14.6% in 2025, driven by double-digit growth in China and India.
  • Margin Expansion:: Adjusted operating profit rose 5.3%, with Core Reckitt margins widening 90 bps to 26.7% in 2025.
  • Shareholder Returns:: GBP 2.3 billion returned to shareholders via dividends and buybacks in 2025, including a GBP 1.6 billion special dividend.
  • 2026 Guidance:: Revenue growth projected at 4-5%, with EPS growth aligned to medium-term targets despite Essential Home divestment dilution.
  • Cost Efficiency:: Fuel for Growth program delivered 150 bps of savings in 2025, enabling 120 bps increase in brand investment and targeting fixed costs below 19% by 2027.

Segmental Performance

In 2025, Emerging Markets grew 14.6%, led by China and India, while Europe declined 1.4% and North America grew 0.2%. Self Care net revenue increased 3%, Germ Protection grew 8.4%, Household Care declined 0.4%, and Intimate Wellness grew 12.5%. The company's Fuel for Growth program drove meaningful simplification and improved effectiveness, delivering 150 basis points of savings in 2025.

Guidance and Outlook

Reckitt expects to deliver 4-5% net revenue growth in 2026, led by Emerging Markets, and low single-digit growth in Mead Johnson Nutrition. The company aims to exit 2027 with a fixed cost base below 19%. EPS growth is expected to align with the medium-term ambition, despite a dilution headwind from the divestment of Essential Home. The company's guidance for 2026 includes a net revenue growth of 4-5%, which is slightly above analyst estimates of 4.0% revenue growth.

Valuation Metrics

Reckitt's current valuation metrics indicate a P/E Ratio of 50.87, P/B Ratio of 6.15, and EV/EBITDA of 22.21. The Dividend Yield is 8.06%, and the Free Cash Flow Yield is 4.85%. The Net Debt/EBITDA ratio is expected to rise towards 2.5x by half-year 2026, up from 1.6x currently. These metrics suggest that the market is pricing in a certain level of growth and profitability for the company.

Operational Highlights

Reckitt's new organizational structure has benefited emerging markets, and Europe is expected to show improving performance. North America is also performing well, outpacing its categories. The company has a strong innovation pipeline, with launches such as Mucinex 12-hour Cold and Fever. Brand equity investments increased 120 bps as a percentage of sales last year, with a focus on innovations and launches.

Challenges and Risks

Russia currently accounts for about 15% of Core Reckitt's sales in Emerging Markets but is not a driver of growth. The company does not expect significant contributions from Russia. Latin America's like-for-like sales declined mid-single digits in Q4 due to a weaker seasonal OTC business and a subdued trading environment. The tax rate is expected to be around 27% in 2026, reflecting a return to a more structural tax rate.

3. NewsRoom

Card image cap

Haleon hit by weak cold season but strong toothpaste sales keep outlook on track

Apr -29

Source:

Card image cap

Air Fresheners Market to Reach $19.75 Billion by 2030, Driven by Urbanization & Fragrance Innovation - Godrej Consumer Products, Procter & Gamble, and Reckitt Benckiser Group Dominate

Apr -27

Source:

Card image cap

FTSE 100 Live: Stocks wallow as oil tops $100, UK consumer confidence falls

Apr -23

Source:

Card image cap

BCG Reports $14.4 Billion in Revenue, Marking 22nd Consecutive Year of Growth

Apr -23

Source:

Card image cap

Reckitt Misses Q1 Expectations As Sales Rise 1.3%, Shares Drop 21% YTD

Apr -22

Source:

Card image cap

Mideast war weighs on parent of Durex condoms

Apr -22

Source:

Card image cap

FTSE 100 Live: Airline-related stocks drag but oilers rise as Iran seizes ships

Apr -22

Source:

Card image cap

Reckitt Benckiser Group Q1 Earnings Call Highlights

Apr -22

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.50%)

6. Segments

Aerospace & Defense

Expected Growth: 4.5%

Reckitt Benckiser's aerospace and defense segment is poised for growth driven by increasing global security concerns, technological advancements in defense systems, and rising demand for aerospace products and services.

7. Detailed Products

Nurofen

Pain relief medication for headaches, back pain, and other types of pain

Lysol

Disinfectant and cleaning products for homes and institutions

Dettol

Antiseptic and disinfectant products for wound care and surface cleaning

Air Wick

Air fresheners and odor eliminators for homes and cars

Mortein

Insecticides and pest control products for homes and gardens

Veet

Hair removal creams and wax strips for men and women

Clearasil

Acne treatment products for skin care

Scholl

Foot care products for foot health and hygiene

Gaviscon

Heartburn and indigestion relief medication

Mucinex

Expectorant medication for relieving congestion and coughs

8. Reckitt Benckiser Group plc's Porter Forces

Forces Ranking

Threat Of Substitutes

Reckitt Benckiser Group plc operates in a industry where there are few substitutes for its products, however, the threat of substitutes is still present due to the increasing trend of natural and organic products.

Bargaining Power Of Customers

The bargaining power of customers is low due to the fact that Reckitt Benckiser Group plc operates in a industry where customers have limited bargaining power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium due to the fact that Reckitt Benckiser Group plc relies on a few large suppliers for its raw materials.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the industry, including high capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry is high due to the fact that Reckitt Benckiser Group plc operates in a highly competitive industry with many established players.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 49.52%
Debt Cost 4.24%
Equity Weight 50.48%
Equity Cost 4.24%
WACC 4.24%
Leverage 98.11%

11. Quality Control: Reckitt Benckiser Group plc passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Reckitt Benckiser

A-Score: 6.0/10

Value: 1.3

Growth: 5.4

Quality: 5.4

Yield: 6.2

Momentum: 8.5

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Unilever

A-Score: 5.6/10

Value: 1.7

Growth: 4.4

Quality: 4.9

Yield: 7.5

Momentum: 6.5

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Essity

A-Score: 5.5/10

Value: 4.8

Growth: 5.6

Quality: 5.7

Yield: 5.6

Momentum: 1.0

Volatility: 10.0

1-Year Total Return ->

View Full Report
Stock-Card
L'Oréal

A-Score: 5.3/10

Value: 1.7

Growth: 5.8

Quality: 8.0

Yield: 3.1

Momentum: 5.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Beiersdorf

A-Score: 4.1/10

Value: 1.9

Growth: 5.4

Quality: 6.4

Yield: 1.2

Momentum: 0.5

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
DSM-Firmenich

A-Score: 4.0/10

Value: 4.7

Growth: 2.1

Quality: 5.1

Yield: 5.0

Momentum: 1.0

Volatility: 6.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

46.72$

Current Price

46.72$

Potential

-0.00%

Expected Cash-Flows